Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19;8(5):e70826.
doi: 10.1002/hsr2.70826. eCollection 2025 May.

The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE

Stanislav G Leontyev  1 , Elena B Yarovaya  2   3 , Vladimir A Kutsenko  2 , Oleg E Ivlev  2   3 , Anna G Soplenkova  2   3 , Andrey M Semenov  4 , Mikhail P Semenov  4 , Sergey V Ivanov  5 , Yulia A Romashova  5 , Sergey S Markin  5
Affiliations

The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE

Stanislav G Leontyev et al. Health Sci Rep. .

Abstract

Background and aims: Major bleedings are the most limiting factor of the usage of thrombolytic agents in pulmonary embolism (PE), especially in elderly patients. Non-immunogenic staphylokinase is a recombinant staphylokinase with high thrombolytic activity, fibrin selectivity, and low immunogenic properties. We performed a post hoc analysis of safety outcomes in elderly patients with massive PE over 60 years' old who received non-immunogenic staphylokinase in FORPE trial.

Methods: A randomized, open-label, multicenter, parallel-group, noninferiority FORPE trial was conducted at 23 clinical sites in Russia. A total of 310 patients aged 18 years and older with massive PE proven by computed tomography pulmonary angiography, right ventricular dysfunction, and hemodynamic instability were included. The patients were randomized for treatment either the non-immunogenic staphylokinase (15 mg) or alteplase (100 mg). Safety outcomes were hemorrhagic stroke, bleeding types 3 and 5 according to BARC classification within 7 days after randomization.

Results: No cases of hemorrhagic stroke or major bleeding were registered in the non-immunogenic staphylokinase group, whereas there were five incidences (5%) of BARC type 3 + 5 bleedings in the alteplase group (p = 0.03). All major bleedings and fatal hemorrhagic stroke in patients treated with alteplase were registered only in elderly patients over 60 years old.

Conclusion: The FORPE trial showed that the treatment of massive PE with hemodynamic instability with the non-immunogenic staphylokinase was safe in elderly patients over 60 years and can be used in emergency medicine in the real-world clinical practice. Future trials and PE registries are needed to make a final decision on safety of thrombolytic therapy with the non-immunogenic staphylokinase in elderly patients. Trial Registration: ClinicalTrials.gov (NCT04688320).

Keywords: elderly patients; massive pulmonary embolism; non‐immunogenic staphylokinase; randomized clinical trial; thrombolytic therapy.

PubMed Disclaimer

Conflict of interest statement

S.G. Leontyev has received lectureship fees from Aspen, Bayer, Medak, Pfizer, Sanofi, Servier, SuperGene, Takeda and declare a patent issued for a method for the treatment of patients with pulmonary embolism. M.P. Semenov, A.M. Semenov, and S.S. Markin declare a patent issued for a method for the treatment of patients with pulmonary embolism. All other authors report no other conflicts of interest or disclosures.

Figures

Figure 1
Figure 1
CONSORT trial profile.
See this image and copyright information in PMC

References

    1. Berman A. R., “Pulmonary Embolism in the Elderly,” Clinics in Geriatric Medicine 17, no. 1 (2001): 107–130, 10.1016/s0749-0690(05)70109-9. - DOI - PubMed
    1. Meneveau N., Bassand J. P., Schiele F., et al., “Safety of Thrombolytic Therapy in Elderly Patients With Massive Pulmonary Embolism: A Comparison With Nonelderly Patients,” Journal of the American College of Cardiology 22, no. 4 (1993): 1075–1079, 10.1016/0735-1097(93)90418-z. - DOI - PubMed
    1. Collen D., “Staphylokinase: A Potent, Uniquely Fibrin‐Selective Thrombolytic Agent,” Nature Medicine 4 (1998): 279–284, 10.1038/nm0398-279. - DOI - PubMed
    1. Markin S. S., Semenov A. M., Markov V. A., Nizov A. A., Ponomarev E. A., and Lebedev P. A., “Clinical Trial of Fibrinselective Thrombolytic Pharmaceutical Agent Fortelyzin (III Phase),” RUDN Journal of Medicine 1 (2012): 105–110.
    1. Kirienko A. I., Leontyev S. G., Tereschenko S. N., et al., “Non‐Immunogenic Recombinant Staphylokinase Versus Alteplase for Patients With Massive Pulmonary Embolism: A Randomized Open‐Label, Multicenter, Parallel‐Group, Non‐Inferiority Trial, FORPE,” Journal of Thrombosis and Haemostasis 23, no. 2 (2025): 657–667, 10.1016/j.jtha.2024.09.035. - DOI - PubMed

Associated data

LinkOut - more resources